Ignite Creation Date:
2024-05-06 @ 2:06 AM
Last Modification Date:
2024-10-26 @ 11:13 AM
Study NCT ID:
NCT01962428
Status:
COMPLETED
Last Update Posted:
2016-11-09
First Post:
2013-10-10
Brief Title:
Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI
Sponsor:
General Hospital of Chinese Armed Police Forces
Organization:
General Hospital of Chinese Armed Police Forces
Study Overview
Official Title:
Randomized Trial of Different Loading Dose of Ticagrelor for Antiplatelet Effect in Patients With Non -ST-segment Elevation ACS Undergoing Percutaneous Coronary Intervention
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It is designed to test the hypothesis that high loading dose360mg ticagrelor versus conventional loading dose180mg will result in a higher inhibition of platelet aggregationIPA without increasing the bleeding events
Detailed Description:
After providing written informed consent all patients will be randomized to receive ticagrelor 360mg or 180mg loading doseLDthen 90mg bid maintenance dose starting 12 hours after LDPCI will performed in 2h-72h after they are given the loading doseAll patients should receive acetylsalicylic acid ASA 75 to 100 mg daily unless intolerantIPA at 0 05 1 2 8 24h after the loading dose of ticagrelor will be measured CK-MB troponin I myoglobin CRP will be detected at 0h before PCI 8h after PCI 24h after PCI ECG will be conducted at 0h and within 24h after PCI Patients returned 28 days for follow-up visits after the loading dose of ticagrelor documented any adverse events
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None